Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial
- María Díez-Campelo
- , Félix López-Cadenas
- , Blanca Xicoy
- , Eva Lumbreras
- , Teresa González
- , Mónica del Rey González
- , Joaquín Sánchez-García
- , Rosa Coll Jordà
- , Bohrane Slama
- , Jose Ángel Hernández-Rivas
- , Sylvain Thepot
- , Teresa Bernal
- , Agnès Guerci-Bresler
- , Joan Bargay
- , María Luz Amigo
- , Claude Preudhomme
- , Laurene Fenwarth
- , Uwe Platzbecker
- , Katharina S. Götze
- , Ali Arar
- Hospital Universitario de Salamanca
- Institute of Biomedical Research of Salamanca (IBSAL)
- University Hospital Germans Trias i Pujol
- Universitat Autònoma de Barcelona (UAB)
- Hospital Universitario Reina Sofía
- Maimonides Institute for Research in Biomedicine (IMIBIC)
- IAS-CSIC and University of Cordoba
- Hospital Universitari de Girona Dr. Josep Trueta
- CH Avignon
- Hospital Infanta Leonor
- University Hospital Angers
- Hospital Central de Asturias
- CHUde Nancy Brabois
- Hospital Son Llàtzer
- Institut d’Investigacio Sanitaria Illes Balears (IdISBa)
- Hospital Morales Meseguer
- University of Lille
- CHRU Roger Salengro
- University Hospital Leipzig
- Service d' Oncologie Médicale Hopital de la Source
- Universidad de Salamanca
- Univ-Paris Diderot Sorbonne Paris-Cité
Research output: Contribution to journal › Article › peer-review
20
Scopus
citations